National Cancer Institute: Cancer Detection, Diagnosis, and Treatment Technologies Grant for Global Health (UH2/UH3)

The National Cancer Institute is offering a grant to develop cancer-related technologies for low- and middle-income countries. This grant seeks to adapt existing technologies into affordable devices for imaging, detection, diagnosis, prevention, or treatment of cancers. The funding will be provided through the UH2/UH3 phased innovation award. Applicants need a working prototype, with the UH2 phase focusing on feasibility and clinical potential in LMICs before transitioning to the UH3 phase for technology validation. Multidisciplinary teams with expertise in engineering, oncology, healthcare delivery, and business development are encouraged to apply. Closing date for applications is March 6, 2015.

Opportunity ID: 269791

Apply

General Information

Document Type::	Grants Notice
Funding Opportunity Number::	RFA-CA-15-001
Funding Opportunity Title::	Cancer Detection, Diagnosis, and Treatment Technologies for Global Health (UH2/UH3)
Opportunity Category::	Discretionary
Opportunity Category Explanation::
Funding Instrument Type::
Category of Funding Activity::	Education
Category Explanation::
Expected Number of Awards::	6
Assistance Listings Number(s)::	93.286 — Discovery and Applied Research for Technological Innovations to Improve Human Health
Cost Sharing or Matching Requirement::	No
Version::	Synopsis 1
Posted Date::	Nov 24, 2014
Last Updated Date::
Original Closing Date for Applications::	Mar 06, 2015
Current Closing Date for Applications::	Mar 06, 2015
Archive Date::	Apr 06, 2015
Estimated Total Program Funding::	$ 3,000,000
Award Ceiling::	$1,000,000
Award Floor::	$

Eligibility

Eligible Applicants::

Native American tribal organizations (other than Federally recognized tribal governments)

Additional Information on Eligibility::

Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name::	National Institutes of Health
Description::	This Funding Opportunity Announcement (FOA) is an initiative to support the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost devices or assays that are clinically comparable to currently used technologies for imaging, in vitro detection/diagnosis, prevention or treatment of cancers in humans living in LMICs. Funds will be made available through the UH2/UH3 phased innovation cooperative agreement award mechanism. Applicants should have a working assay or prototype (not necessarily already capable of cancer applications). The initial UH2 exploratory phase will be a feasibility study to demonstrate technical functionality and clinical potential for use in LMIC settings by meeting specific performance milestones. UH2 projects that have met their milestones will be administratively considered by NCI and NIBIB and subsequently prioritized for transition to the UH3 validation phase. UH3 awards will support improvements and validations of the technologies in the LMIC settings. Projects proposed in response to this FOA will require multidisciplinary efforts to succeed and therefore all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this FOA must address both UH2 and UH3 phases.
Link to Additional Information::
Grantor Contact Information::	If you have difficulty accessing the full announcement electronically, please contact:

Version History

Version	Modification Description	Updated Date
Synopsis 1

Package Status

Below are CLOSED Opportunity Package(s) no longer available for this Funding Opportunity:

Package No: 1

Assistance Listings:
Competition ID:	FORMS-C
Competition Title:	FORMS-C
Opportunity Package ID:	PKG00210085
Opening Date:	Feb 06, 2015
Closing Date:	Mar 06, 2015
Agency Contact Information::	eRA Commons Help Desk Monday to Friday 7 am to 8 pm ET http://grants.nih.gov/support/
Who Can Apply::	Organization Applicants
mendatory_forms	SF424 (R & R) [V2.0] PHS 398 Research Plan [V2.0] PHS 398 Cover Page Supplement [V2.0] Research & Related Budget [V1.3] Research and Related Senior/Key Person Profile (Expanded) [V2.0] Research And Related Other Project Information [V1.3] Project/Performance Site Location(s) [V2.0]
optional_forms	Planned Enrollment Report [V1.0] PHS 398 Cumulative Inclusion Enrollment Report [V1.0] R & R Subaward Budget Attachment(s) Form 5 YR 30 ATT [V1.3]

Packages